- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07913165
A Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Refractory to ≥ Second-Line Chemotherapy
An Open-Label, Single-Arm, Single-Center Study of Trifluridine/Tipiracil (TAS-102) Combined With Nedaplatin for Patients With Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Refractory to ≥2 Prior Lines of Chemotherapy
This study aims to evaluate the efficacy and safety of TAS-102 combined with nedaplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma who have experienced disease progression after two or more lines of prior chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Zhenyu Lin
- Phone Number: 027-85871982
- Email: whxhlzy@hust.edu.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-
Age: 18-75 years;
-
Performance Status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;
-
Diagnosis: Histologically or pathologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction;
-
Prior Treatment: Disease progression or failure after receiving second-line or later chemotherapy;
-
TNM Stage: TNM Stage IV (TanyNanyM1);
-
Measurable Disease: Presence of at least one radiologically evaluable lesion per RECIST v1.1 criteria (or other applicable criteria) within 21 days prior to enrollment;
-
Adequate Organ Function: Defined as follows within specified timeframes before enrollment;
-
Hematology:
- Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹/L
- Platelet count (PLT) ≥ 90 × 10⁹/L
- Hemoglobin (Hb) ≥ 90 g/L
-
Biochemistry:
- Total Bilirubin (TBIL) ≤ Upper Limit of Normal (ULN)
- Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 1.5 × ULN
- Alkaline Phosphatase (ALP) ≤ 2.5 × ULN
- Blood Urea Nitrogen (BUN) and Serum Creatinine (Cr) ≤ 1.5 × ULN
- Creatinine Clearance (CrCl) ≥ 50 mL/min (calculated using the Cockcroft-Gault formula)
-
Coagulation:
- International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × ULN
- Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 × ULN
-
Cardiac Function:
- Left Ventricular Ejection Fraction (LVEF) ≥ 55% as measured by Echocardiography (ECHO) or Multigated Acquisition Scan (MUGA)
- Corrected QT interval using Fridericia's formula (QTcF) < 470 ms for females and < 450 ms for males on Electrocardiogram (ECG);
-
-
Informed Consent: Voluntarily provide written informed consent prior to any study-specific procedures.
Exclusion Criteria:
-
Prior TAS-102: Previous treatment with TAS-102;
-
Concurrent Anticancer Therapy: Concurrent participation in another clinical trial involving anticancer therapy;
-
Recent Major Surgery: Undergone major surgical procedures within 4 weeks prior to enrollment, or has not fully recovered from such procedures;
-
Significant Cardiac Disease: History or presence of clinically significant cardiac disease, including but not limited to:
- History of congestive heart failure (CHF) or systolic dysfunction (LVEF < 50%).
- High-risk uncontrolled arrhythmias, significant ventricular arrhythmia (e.g., ventricular tachycardia), or high-grade atrioventricular block.
- Angina pectoris requiring anti-anginal medication.
- Clinically significant valvular heart disease.
- ECG evidence of transmural myocardial infarction.
- Poorly controlled hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 100 mmHg);
-
General Exclusion: Any other condition that, in the judgment of the Investigator, would make the subject unsuitable for participation in the study or compromise protocol compliance.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: TAS-102 plus nedaplatin
|
TAS-102:35mg/m2(BID, D1-5, D8-12)Q4W, 6 cycles + Nedaplatin:80-100mg/m2 Q4W, 6 cycles |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Progression-free survival (PFS)
Time Frame: Through out the study (up to 2 years)
|
The efficacy of solid tumors was evaluated according to RECIST v1.1 |
Through out the study (up to 2 years)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective response rate (ORR)
Time Frame: Through out the study (up to 2 years)
|
The efficacy of solid tumors was evaluated according to Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v1.1). |
Through out the study (up to 2 years)
|
|
Disease control rate (DCR)
Time Frame: Through out the study (up to 2 years)
|
The efficacy of solid tumors was evaluated according to RECIST v1.1 |
Through out the study (up to 2 years)
|
|
Overall survival (OS)
Time Frame: Through out the study (up to 2 years)
|
The efficacy of solid tumors was evaluated according to RECIST v1.1 |
Through out the study (up to 2 years)
|
|
Adverse Event (AE), Treatment-Emergent AE (TEAE), Adverse Event of Special Interest (AESI) and Serious Adverse Event (SAE)
Time Frame: Through out the study (up to 2 years)
|
Adverse events will be assessed by investigator(s) according to Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE v5.0). |
Through out the study (up to 2 years)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TAS-102-GAS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.